Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis

Review of 42 studies (n=5,326) found that the combination treatments evaluated did not improve overall survival compared with lomustine monotherapy and were often associated with a higher risk of severe adverse events

Source:

Cochrane Database of Systematic Reviews